menu
    • menu
    [{"orgOrder":0,"company":"AstraZeneca","sponsor":"Cheplapharm Arzneimittel Gmbh","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Divestment","leadProduct":"Candesartan Cilexetil","moa":"AT1 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Cheplapharm Arzneimittel Gmbh","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Cheplapharm Arzneimittel Gmbh"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Cheplapharm Arzneimittel Gmbh","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Divestment","leadProduct":"Candesartan Cilexetil","moa":"AT1 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Cheplapharm Arzneimittel Gmbh","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Cheplapharm Arzneimittel Gmbh"},{"orgOrder":0,"company":"Apontis Pharma","sponsor":"Midas Pharma","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2021","type":"Partnership","leadProduct":"Candesartan Cilexetil","moa":"||AT1 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Apontis Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Apontis Pharma \/ Midas Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Apontis Pharma \/ Midas Pharma"}]

    Find Clinical Drug Pipeline Developments & Deals for Atacand

    Menu

    Atacand

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
    filter

    Year

    filter

    DEALS // DEV.

    filter

    Country

    filter
    Sponsor
    filter

    Therapeutic Area

    filter

    Study Phase

    filter

    Deal Type

    filter

    Product Type

    filter

    Dosage Form

    filter

    Lead Product

    filter

    Target

    refresh Filters
    refresh Reset Filter
    refresh Reset Filter
    price-trend All Developments

    Therapeutic Area by Lead Product

    ForexGraph

    Study Phase by Lead Product

    ForexGraph

    Company by Lead Product

    ForexGraph

    Top Deals by Deal Size (USD bn)

    ForexGraph

    01

    Apontis Pharma

    Germany arrow
    German Wound Congress
    Not Confirmed

    Apontis Pharma

    Germany arrow
    German Wound Congress
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Candesartan Cilexetil,Amlodipine Besylate,Atorvastatin

    Therapeutic Area : Cardiology/Vascular Diseases

    Study Phase : Phase III

    Sponsor : Midas Pharma

    Deal Size : Undisclosed

    Deal Type : Partnership

    DEALS_DEV arrow-down

    APONTIS PHARMA and Midas Pharma Announce Development Partnership to Launch Single Pill with Pan-european Intel...

    Details : The objective is the contract development of a Single Pill with a combination of three leading active ingredients, including candesartan cilexetil, amlodipine besylate and atorvastatin calcium trihydrate for the treatment of high blood pressure (hyperten...

    Product Name : Undisclosed

    Product Type : Other Small Molecule

    Upfront Cash : Undisclosed

    December 14, 2021

    Lead Product(s) : Candesartan Cilexetil,Amlodipine Besylate,Atorvastatin

    Therapeutic Area : Cardiology/Vascular Diseases

    Highest Development Status : Phase III

    Sponsor : Midas Pharma

    Deal Size : Undisclosed

    Deal Type : Partnership

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    02

    AstraZeneca

    United Kingdom arrow
    German Wound Congress
    Not Confirmed

    AstraZeneca

    United Kingdom arrow
    German Wound Congress
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Candesartan Cilexetil

    Therapeutic Area : Cardiology/Vascular Diseases

    Study Phase : Approved FDF

    Sponsor : Cheplapharm Arzneimittel Gmbh

    Deal Size : $400.0 million

    Deal Type : Divestment

    DEALS_DEV arrow-down

    AstraZeneca's Atacand Divestment to Cheplapharm in More than 70 Countries Completed

    Details : AstraZeneca has completed the divestment of commercial rights to Atacand (candesartan cilexetil) and Atacand Plus (a fixed-dose combination of candesartan cilexetil and hydrochlorothiazide) in over 70 countries to Cheplapharm Arzneimittel GmbH (Cheplapha...

    Product Name : Atacand

    Product Type : Other Small Molecule

    Upfront Cash : Undisclosed

    April 01, 2021

    Lead Product(s) : Candesartan Cilexetil

    Therapeutic Area : Cardiology/Vascular Diseases

    Highest Development Status : Approved FDF

    Sponsor : Cheplapharm Arzneimittel Gmbh

    Deal Size : $400.0 million

    Deal Type : Divestment

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    03

    AstraZeneca

    United Kingdom arrow
    German Wound Congress
    Not Confirmed

    AstraZeneca

    United Kingdom arrow
    German Wound Congress
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Candesartan Cilexetil

    Therapeutic Area : Cardiology/Vascular Diseases

    Study Phase : Approved FDF

    Sponsor : Cheplapharm Arzneimittel Gmbh

    Deal Size : $400.0 million

    Deal Type : Divestment

    DEALS_DEV arrow-down

    Astrazeneca's Atacand to be Divested to Cheplapharm in More than 70 Countries

    Details : AstraZeneca would sell rights for its heart failure and blood pressure medicines Atacand and Atacand Plus to Germany’s Cheplapharm Arzneimittel GmbH. Agreement supports strategy of focusing on newer medicines in main therapy areas.

    Product Name : Atacand

    Product Type : Other Small Molecule

    Upfront Cash : Undisclosed

    October 30, 2020

    Lead Product(s) : Candesartan Cilexetil

    Therapeutic Area : Cardiology/Vascular Diseases

    Highest Development Status : Approved FDF

    Sponsor : Cheplapharm Arzneimittel Gmbh

    Deal Size : $400.0 million

    Deal Type : Divestment

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth